- In May 2024, Novo Nordisk A/S launched a real-world evidence study for its centrally acting GLP-1 receptor agonist Wegovy across multiple regions, aiming to evaluate long-term safety, adherence, and cardiovascular outcomes in obese patients. The study underscores the company's commitment to advancing clinical validation and expanding access to its innovative centrally acting therapies as demand surges for pharmacological solutions to obesity
- In April 2024, Eli Lilly and Company announced the FDA approval of Zepbound (tirzepatide), a dual GIP/GLP-1 receptor agonist with central nervous system activity, for chronic weight management. This marks a significant milestone in the obesity therapeutics landscape, with Zepbound offering substantial efficacy in appetite suppression and metabolic regulation. The launch positions Lilly at the forefront of centrally acting obesity drug development
- In March 2024, Currax Pharmaceuticals LLC expanded the distribution of its centrally acting obesity drug, Contrave (naltrexone HCl/bupropion HCl), into several new European markets following regulatory clearance. The move reflects the company’s strategic intent to globalize access to prescription weight-loss medications and cater to the growing demand for combination anorectic therapies with central activity.
- In February 2024, Gelesis Inc. initiated clinical trials for a next-generation hydrogel-based anorectic formulation with central effects targeting neurohormonal pathways involved in appetite regulation. While the company is best known for its mechanical appetite suppressants, this innovation signals a diversification into centrally acting modalities, aligning with emerging trends in obesity pharmacotherapy.
- In January 2024, Amgen Inc. announced promising Phase 1 trial results for AMG 133, a novel GLP-1 receptor and GIPR agonist with central mechanisms of action. The candidate demonstrated significant appetite reduction and weight loss in obese individuals, prompting advancement to late-stage clinical trials. The development reflects Amgen's entry into the rapidly evolving market of CNS-targeted obesity treatments
